Pfizer to Launch its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019

 Pfizer to Launch its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019

Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA’s Approval for Transthyretin Amyloid Cardiomyopathy


  • The biosimilar launch in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept 2019, Genentech and Pfizer signed a joint stipulation of dismissal in their patent litigation case and voluntarily dismissed all the claims and counterclaims of April 2019 complaint
  • Genentech alleged that Pfizer had not produced all necessary information concerning Avastin, and claimed that the biosimilar would infringe 23 of its patents
  • Zirabev (bevacizumab-bvzr) is a mAb inhibits formation of new blood cells (angiogenesis) approved by the US FDA in Jun’2019 for MCC, unresectable/LA/recurrent or mnon-sq NSCLC, recurrent glioblastoma, mRCC, and persistent, recurrent or metastatic cervical cancer and also received EC’s approval in Feb’2019

Click here to­ read full press release/ article | Ref: Center for Biosimilars | Image: Wunc

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post